Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective was to confirm the effect of tasquinimod in delaying disease
progression or death as compared with placebo in chemo-naïve patients with metastatic
castrate-resistant prostate cancer (mCRPC).
Secondary objectives included further evaluation of the safety profile of tasquinimod,
comparison of clinical benefits (such as overall survival and symptoms) of tasquinimod with
placebo, to evaluate the quality of life impact and to determine the pharmacokinetics of
tasquinimod.